Journal article
A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer
Abstract
The purpose of this study was to determine the recommended phase II dose of liposomal doxorubicin (Caelyx ; Doxil in the United States) in combination with cyclophosphamide and vincristine for previously treated patients with good performance status with relapsed or refractory small-cell lung cancer. Twenty-one eligible patients were enrolled between November 1999 and September 2001 and received liposomal doxorubicin 25-40 mg/m2, …
Authors
Leighl NB; Burkes RL; Dancey JE; Lopez PG; Higgins BP; Walde PLD; Rudinskas LC; Rahim YH; Rodgers A; Pond GR
Journal
Clinical Lung Cancer, Vol. 5, No. 2, pp. 107–112
Publisher
Elsevier
Publication Date
9 2003
DOI
10.3816/clc.2003.n.024
ISSN
1525-7304